Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial
Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Min Yan(Henan Cancer Hospital), Fei Ma(Chinese Academy of Medical Sciences & Peking Union Medical College), Xichun Hu(Fudan University Shanghai Cancer Center), Jifeng Feng(Jiangsu Cancer Hospital), Quchang Ouyang(Hunan Cancer Hospital), Zhongsheng Tong(Tianjin Medical University Cancer Institute and Hospital), Huiping Li(Peking University), Qingyuan Zhang(Harbin Medical University), Tao Sun(Liaoning Cancer Hospital & Institute), Xian Wang(Sir Run Run Shaw Hospital), Yongmei Yin(Nanjing Medical University), Ying Cheng(Jilin Province Tumor Hospital), Wěi Li(First Bethune Hospital of Jilin University), Yuanting Gu(First Bethune Hospital of Jilin University), Qianjun Chen(Guangdong Provincial Hospital of Traditional Chinese Medicine), Jinping Liu(Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital), Jing Cheng(Wuhan Union Hospital), Cuizhi Geng(Fourth Hospital of Hebei Medical University), Shukui Qin(Nanjing General Hospital of Nanjing Military Command), Shusen Wang(Sun Yat-sen University Cancer Center), Jinsong Lu(Renji Hospital), Kunwei Shen(Ruijin Hospital), Qiang Liu(Sun Yat-sen University), Xiaojia Wang(Sir Run Run Shaw Hospital), Hong Wang(Third Hospital of Nanchang), Ting Luo(West China Hospital of Sichuan University), Jin Yang(First Affiliated Hospital of Xi'an Jiaotong University), Yudong Wu(Jiangxi Provincial Cancer Hospital), Zhiyong Yu(Shandong First Medical University), Xiaoyu Zhu(Jiangsu Hengrui Medicine (China)), Chunxia Chen(Jiangsu Hengrui Medicine (China)), Jianjun Zou(Jiangsu Hengrui Medicine (China))
Cited by 388